Kiniksa Pharmaceuticals International, plc KNSA Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's accounts payable?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported accounts payable of $24.4M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's accounts payable changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's accounts payable increased by 1131.2% year-over-year, from $1.98M to $24.4M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's accounts payable?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's accounts payable has grown at a 32.2% compound annual growth rate (CAGR), from $503K to $2.03M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.